Literature DB >> 32164343

MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells.

Zélia Silva1, Tiago Ferro1,2, Danielle Almeida1, Helena Soares3, José Alexandre Ferreira4,5, Fanny M Deschepper1, Paul J Hensbergen6, Martina Pirro6, Sandra J van Vliet7, Sebastian Springer8, Paula A Videira1,2.   

Abstract

Maturation of human Dendritic Cells (DCs) is characterized by increased expression of antigen presentation molecules, and overall decreased levels of sialic acid at cell surface. Here, we aimed to identify sialylated proteins at DC surface and comprehend their role and modulation. Mass spectrometry analysis of DC's proteins, pulled down by a sialic acid binding lectin, identified molecules of the major human histocompatibility complex class I (MHC-I), known as human leucocyte antigen (HLA). After desialylation, DCs showed significantly higher reactivity with antibodies specific for properly folded MHC-I-β2-microglobulin complex and for β2-microglobulin but showed significant lower reactivity with an antibody specific for free MHC-I heavy chain. Similar results for antibody reactivities were observed for TAP2-deficient lymphoblastoid T2 cells, which express HLA-A*02:01. Using fluorescent peptide specifically fitting the groove of HLA-A*02:01, instead of antibody staining, also showed higher peptide binding on desialylated cells, confirming higher surface expression of MHC-I complex. A decay assay showed that desialylation doubled the half-life of MHC-I molecules at cell surface in both DCs and T2 cells. The biological impact of DC´s desialylation was evaluated in co-cultures with autologous T cells, showing higher number and earlier immunological synapses, and consequent significantly increased production of IFN-γ by T cells. In summary, sialic acid content modulates the expression and stability of complex MHC-I, which may account for the improved DC-T synapses.

Entities:  

Keywords:  cancer-vaccines; dendritic-cells, antigen-presentation, MHC-I, immunogenicity, T-cell response

Year:  2020        PMID: 32164343     DOI: 10.3390/pharmaceutics12030249

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  6 in total

Review 1.  Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.

Authors:  Przemyslaw Wielgat; Karol Rogowski; Katarzyna Niemirowicz-Laskowska; Halina Car
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

2.  Sialic acid blockade in dendritic cells enhances CD8+ T cell responses by facilitating high-avidity interactions.

Authors:  N Balneger; L A M Cornelissen; M Wassink; S J Moons; T J Boltje; Y E Bar-Ephraim; K K Das; J N Søndergaard; C Büll; G J Adema
Journal:  Cell Mol Life Sci       Date:  2022-01-28       Impact factor: 9.261

3.  Concerted Regulation of Glycosylation Factors Sustains Tissue Identity and Function.

Authors:  Daniel Sobral; Rita Francisco; Laura Duro; Paula Alexandra Videira; Ana Rita Grosso
Journal:  Biomedicines       Date:  2022-07-27

4.  Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation.

Authors:  Devin Dersh; Jonathan W Yewdell
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

5.  HLA class-I-peptide stability mediates CD8+ T cell immunodominance hierarchies and facilitates HLA-associated immune control of HIV.

Authors:  Clarety Kaseke; Ryan J Park; Nishant K Singh; Dylan Koundakjian; Arman Bashirova; Wilfredo F Garcia Beltran; Overbeck C Takou Mbah; Jiaqi Ma; Fernando Senjobe; Jonathan M Urbach; Anusha Nathan; Elizabeth J Rossin; Rhoda Tano-Menka; Ashok Khatri; Alicja Piechocka-Trocha; Michael T Waring; Michael E Birnbaum; Brian M Baker; Mary Carrington; Bruce D Walker; Gaurav D Gaiha
Journal:  Cell Rep       Date:  2021-07-13       Impact factor: 9.423

6.  Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients.

Authors:  Mepur H Ravindranath; Narendranath M Ravindranath; Fatiha El Hilali; Senthamil R Selvan; Edward J Filippone
Journal:  Antibodies (Basel)       Date:  2022-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.